DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Depen (Penicillamine) - Summary

 
 



Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. Patients should be warned to report promptly any symptoms suggesting toxicity.

 

DEPEN SUMMARY

DEPENĀ®
(penicillamine tablets, USP)
Titratable Tablets

Penicillamine is 3-mercapto-D-valine, a disease modifying antirheumatic drug. It is a white or practically white, crystalline powder, freely soluble in water, slightly soluble in alcohol, and insoluble in ether, acetone, benzene, and carbon tetrachloride. Although its configuration is D, it is levorotatory as usually measured.

DEPEN is indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that DEPEN is not of value in ankylosing spondylitis.
See all Depen indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Depen (Penicillamine)

Being underweight is an independent risk factor for death after heart attack
Source: Cardiovascular / Cardiology News From Medical News Today [2016.04.19]
Low body mass index increases risk mortality after acute myocardial infarction (AMI), even after adjustment for other health factors that affect body weight, according to a study in PLOS Medicine.

Researchers discover that breast cancer tumor growth is dependent on lipid availability
Source: Breast Cancer News From Medical News Today [2016.04.06]
In an article published in Nature Communications, the researchers report that breast cancer cells need to take up lipids from the extracellular environment in order to continue proliferating.

Anti-Addiction Drug May Help Curb Painkiller, Heroin Dependence
Source: MedicineNet Chronic Pain Specialty [2016.03.31]
Title: Anti-Addiction Drug May Help Curb Painkiller, Heroin Dependence
Category: Health News
Created: 3/30/2016 12:00:00 AM
Last Editorial Review: 3/31/2016 12:00:00 AM

States where midwives practice independently have lower rates of cesarean deliveries
Source: Nursing / Midwifery News From Medical News Today [2016.03.09]
States that allow autonomous practice by certified nurse-midwives (CNMs) have a higher proportion of CNM-attended births as well as lower rates of cesarean sections, preterm births, and low...

Conversion of head and neck cancer cells into radiation-resistant cancer stem cells depends on HPV status, UCLA-led study finds
Source: Ear, Nose and Throat News From Medical News Today [2016.02.10]
Head and neck cancers that test positive for the human papilloma virus (HPV) are known to respond more favorably to radiation therapy than those that test HPV-negative, but an explanation for these...

more news >>

Published Studies Related to Depen (Penicillamine)

Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo-controlled trial. [2010.09]
PURPOSE: To compare prophylactic enteral D-penicillamine (DPA) with placebo for prevention of 'retinopathy of prematurity (ROP) or death' among very low birth weight (VLBW) infants... CONCLUSION: Prophylactic enterally administered DPA suspension in a dose 100 mg/kg/dose 8 h for 3 days, followed by 50 mg/kg once per day for next 11 days, does not prevent 'any stage ROP or death' or 'ROP requiring treatment' in VLBW infants. DPA is well tolerated and does not have any major short-term adverse effects. (c) 2010 The Author(s)/Journal Compilation (c) 2010 Foundation Acta Paediatrica.

Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo-controlled trial. [2010.04.16]
Abstract Purpose: To compare prophylactic enteral D-penicillamine (DPA) with placebo for prevention of 'retinopathy of prematurity (ROP) or death' among very low birth weight (VLBW) infants. Methods: This was a double-blind, single-centre, randomized, placebo-controlled trial with stratification (for birth weight <1250 and >/=1250 g) and blocking...

D-Penicillamine for preventing retinopathy of prematurity in preterm infants. [2013]
CONCLUSIONS: Administration of prophylactic D-penicillamine in preterm

D-penicillamine, a potent melanogenesis inhibitor, lacks any depigmenting effect on black guinea pig skin: the first randomized, evaluator-blinded, vehicle-controlled, in vivo study. [2011.06]
D-penicillamine is a melanogenesis inhibitor. This in vivo study on ten black guinea pigs using a 5% D-penicillamine ointment showed its lack of any skin-lightening effect.The potential reasons for this ineffectiveness are discussed in the paper, which could be very helpful for researchers exploring new skin-lightening agents.

D-penicillamine elastosis perforans serpiginosa: description of two cases and review of the literature. [2011.04.15]
Long term D-penicillamine (DPA) therapy to treat Wilson disease can induce elastosis perforans serpiginosa (EPS), a very rare degenerative skin disease characterized by a transepidermal elimination of elastic fiber aggregates.

more studies >>

Clinical Trials Related to Depen (Penicillamine)

Post Marketing Surveillance Study of Cuprimine [No longer available]
Cuprimine (penicillamine) was made available in the Philippines by the Sponsor under a Compassionate Special Permit issued by the Bureau of Food and Drugs. Physicians were able to request the drug for their patients from the Sponsor. A Clinical Study Report form was completed for each purchase of Cuprimine.

Penicillamine, Low Copper Diet, and Radiation Therapy in Treating Patients With Glioblastoma [Completed]
RATIONALE: Penicillamine may stop the growth of glioblastomas by stopping blood flow to the tumor. A diet low in copper may interfere with the growth of brain tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these therapies may be effective in treating glioblastoma. PURPOSE: Phase II trial to study the effectiveness of penicillamine, a low copper diet, and radiation therapy in treating patients who have newly diagnosed glioblastoma.

Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine [Not yet recruiting]
A study to review Wilson disease patients who have previously been prescribed d- Penicillamine but were changed to trientine as treatment for their disease, and to follow them for a further 12 months.

Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria [Recruiting]
The purpose of this study is to evaluate the effect of escalating doses of cystine biding thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger doses.

Cystine Capacity Clinical Study (CysCap) [Recruiting]
The purpose of this study is to determine whether urinary cystine capacity, an assay used to measure the amount of cystine in the urine, can be used to predict stone recurrence in patients with cystinuria.

more trials >>


Page last updated: 2016-04-19

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015